Expert panel endorse individualized beta-lactam dosing for acutely ill patients - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Expert panel endorse individualized beta-lactam dosing for acutely ill patients

International guidance supports concentration-guided dosing for selected acutely ill patients, with clinical cure showing the clearest benefit.

  • By

  • Doug Brunk

  • August 17, 2026

  • 7 min

Share

Objective:

To evaluate the effectiveness of individualized beta-lactam dosing guided by measured drug levels in critically ill patients.

Approach:
  • Panel Composition: A 19-member international panel of experts in various fields convened to develop recommendations.
  • Evidence Review: The panel conducted a systematic review of research databases and clinical trial registries, screening studies and extracting data.
  • Consensus Development: When evidence was insufficient, expert consensus was used to develop best-practice statements.
Key Findings:
  • Patients receiving individualized beta-lactam dosing had nearly twice the odds of clinical cure compared to usual care.
  • The evidence for mortality reduction was inconclusive, with no statistically significant difference found.
  • Individualized dosing did not significantly improve microbiologic eradication or shorten hospital stays.
Interpretation:

The panel conditionally recommended individualized dosing for critically ill patients and those with altered kidney function.

Limitations:
  • Few randomized trials and differences in outcome definitions.
  • Uncertainty in results and limited access to rapid drug-level testing.
  • Safety evidence remains unclear, particularly regarding high beta-lactam levels.
Conclusion:

Individualized beta-lactam dosing may improve treatment outcomes.

Sources:

Original Source(s)

Expert panel endorse individualized beta-lactam dosing for acutely ill patients

  • by Doug Brunk

  • August 17, 2026

Related Content

Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.